<!-- page 1 -->

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE** 

## **HEALTH TECHNOLOGY APPRAISAL PROGRAMME** 

## **Equality impact assessment – Guidance development STA Empagliflozin for treating chronic kidney disease** 

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme. 

## **Final Draft Guidance** 

(when draft guidance issued) 

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? 

CKD can progress more quickly in some ethnic minority groups and, in people with type 2 diabetes, it progresses more quickly in people under 55 years. This was acknowledged but could not considered in the decision making. It did not consider these to be equality issues that could be resolved by this appraisal. 

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? 

No 

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? 

No 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of empagliflozin for treating chronic kidney disease [ID6131] 1 of 2 Issue date: November 2023 



<!-- page 2 -->

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? 

No 5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? 

No 

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? 

No 

7. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where? 

Yes - Section 1.3 

## **Approved by Associate Director (name):** …Linda Landells……………… 

## **Date:** 31 October 2023 

Technology appraisals: Guidance development Equality impact assessment for the single technology appraisal of empagliflozin for treating chronic kidney disease [ID6131] 2 of 2 Issue date: November 2023 

